金陵药业(000919) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥662,846,710.06, a decrease of 5.53% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥20,087,506.44, down 40.46% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,944,912.53, a decrease of 32.97% compared to the previous year[5]. - The basic earnings per share for the period was ¥0.0399, reflecting a decline of 39.64% year-on-year[5]. - Total operating revenue for Q3 2023 reached ¥2,104,243,523.41, an increase of 2.3% compared to ¥2,053,856,118.01 in Q3 2022[18]. - Net profit for Q3 2023 was CNY 106,909,525.59, a slight increase from CNY 105,406,239.67 in Q3 2022, representing a growth of approximately 1.43%[19]. - Operating profit for Q3 2023 was CNY 123,356,743.74, compared to CNY 126,771,721.83 in the same period last year, showing a decrease of about 3.22%[19]. - Total comprehensive income for Q3 2023 was CNY 106,909,525.59, down from CNY 119,568,574.16 in the same quarter last year[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,539,711,037.57, a slight decrease of 0.08% from the end of the previous year[5]. - The total assets of the company stood at ¥4,539,711,037.57, slightly down from ¥4,543,352,930.71 at the end of the previous quarter[16]. - Total liabilities decreased to ¥859,400,725.35 from ¥916,299,000.51, indicating a reduction of approximately 6.2%[16]. - The company's total equity increased to ¥3,680,310,312.22, compared to ¥3,627,053,930.20 in the previous quarter, marking an increase of 1.5%[16]. Cash Flow and Investments - Cash flow from operating activities showed a net outflow of ¥7,405,450.81, a significant decline of 105.24% compared to the previous year[10]. - The company's cash and cash equivalents showed a net decrease of ¥579,077,961.15, a 61.16% increase in outflow compared to the previous year[10]. - As of September 30, 2023, the company's cash and cash equivalents amounted to ¥912,076,558.41, down from ¥1,495,023,241.06 at the beginning of the year, representing a decrease of approximately 39%[14]. - Cash and cash equivalents in current assets totaled ¥2,319,556,134.73, down from ¥2,633,145,031.76, a decrease of 11.9%[16]. - Investment activities resulted in a net cash outflow of CNY -519,452,680.25, worsening from CNY -454,515,720.21 in the previous year[22]. Accounts Receivable and Inventory - The company's accounts receivable increased by 63.81% to ¥434,727,012.72, primarily due to increased insurance settlement receivables[9]. - The company reported a 172.06% increase in trading financial assets, totaling ¥251,247,217.79, attributed to increased bank wealth management products[9]. - The company’s accounts receivable increased to ¥434,727,012.72 from ¥265,381,850.28, reflecting a growth of about 63.6%[14]. - The inventory level rose to ¥261,064,676.34 compared to ¥250,483,101.42 at the start of the year, showing a slight increase of about 4.3%[14]. Shareholder Information - The company reported a total of 39,166 common shareholders at the end of the reporting period[11]. - The top shareholder, Nanjing New Industry Investment Group, holds 44.60% of the shares, totaling 227,943,839 shares[11]. - The company has not disclosed any related party transactions or whether the shareholders are acting in concert[11]. Research and Development - Research and development expenses were ¥42,194,094.46, a decrease of 6.5% from ¥45,168,326.22 in the previous year[18]. - The company signed a cooperation agreement with Nanjing Aide Kaiteng Biopharmaceutical Co., Ltd. to jointly develop "intermediate phenolic raw materials and orally disintegrating tablets"[12]. - The company received the IV phase clinical trial summary report for its product "Shu Ling Jian Pi Jiao Nang" from its subsidiary, Fuzhou Meifeng Pharmaceutical Factory[12]. Future Outlook - The company plans to expand its market presence and invest in new product development to drive future growth[16]. - The company has maintained a stable dividend policy, with retained earnings increasing to ¥1,672,484,208.36, supporting future investments and shareholder returns[16].